Literature DB >> 21798243

Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.

Hedvig Welander1, Sai Vineela Bontha, Thomas Näsström, Mikael Karlsson, Fredrik Nikolajeff, Karin Danzer, Marcus Kostka, Hannu Kalimo, Lars Lannfelt, Martin Ingelsson, Joakim Bergström.   

Abstract

Deposition of fibrillar α-synuclein as Lewy bodies is the neuropathological hallmark of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Apart from α-synuclein, these intraneuronal inclusions contain over 250 different proteins. The actin binding protein gelsolin, has previously been suggested to be part of the Lewy body, but its potential role in α-synuclein aggregation remains unknown. Here, we studied the association between gelsolin and α-synuclein in brain tissue from PD and DLB patients as well as in a cell model for α-synuclein aggregation. Moreover, the potential effect of gelsolin on α-synuclein fibrillization was also investigated. Our data demonstrate that gelsolin co-occured with α-synuclein in Lewy bodies from affected human brain as well as with Lewy body-like inclusions in α-synuclein over expressing cells. Furthermore, in the presence of calcium chloride, gelsolin was found to enhance the aggregation rate of α-synuclein in vitro. Moreover, no apparent structural differences could be observed between fibrils formed in the presence or absence of gelsolin. Further studies on gelsolin and other Lewy body associated proteins are warranted to learn more about their potential role in the α-synuclein aggregation process.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21798243     DOI: 10.1016/j.bbrc.2011.07.027

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.

Authors:  André S L M Antunes; Valéria de Almeida; Fernanda Crunfli; Victor C Carregari; Daniel Martins-de-Souza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

3.  Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease.

Authors:  Ruilai Jiang; Chunjiao Rong; Ronghu Ke; Shuiyan Meng; Xiumei Yan; Honglin Ke; Shaochang Wu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

4.  Comprehensive proteomic profiling of plasma-derived Extracellular Vesicles from dementia with Lewy Bodies patients.

Authors:  Ana Gámez-Valero; Jaume Campdelacreu; Ramón Reñé; Katrin Beyer; Francesc E Borràs
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.